Storyline
Regeneron's LAG-3 inhibitor fails phase 3 melanoma trial, marking second late-stage setback
Regeneron's phase 3 trial of its LAG-3 inhibitor fianlimab combined with Libtayo in melanoma failed to meet its primary endpoint, not significantly outperforming Keytruda. This unexpected result represents the company's second major late-stage clinical failure within a year and led to a sharp decline in market value.
Published 2026-05-18 08:58 UTCUpdated 2026-05-18 11:55 UTC
Current brief openSource links open
This current storyline is open here with summary, metadata, source links, continuity context, and full evidence. Paid is for compare-over-time, alerts, exports, and workflow.
No card needed for the free brief.
Evidence trail (top sources)
top sources (3 domains)domains are deduped. counts indicate coverage, not truth.3 top sources shown
Overview
Regeneron's phase 3 trial of its LAG-3 inhibitor fianlimab combined with Libtayo in melanoma failed to meet its primary endpoint, not significantly outperforming Keytruda. This unexpected result represents the company's second major late-stage clinical failure within a year and led to a sharp decline in market value.
Score total
1.27
Momentum 24h
3
Posts
3
Origins
3
Source types
1
Duplicate ratio
0%
Why now
- Results were recently announced, marking a fresh setback for Regeneron.
- Follows a prior late-stage trial failure within the past year, compounding concerns.
- Market reaction was immediate, wiping out billions in company valuation.
Why it matters
- Highlights challenges in developing effective LAG-3 inhibitors for cancer immunotherapy.
- Signals potential delays or setbacks in Regeneron's oncology drug pipeline.
- Impacts investor and market confidence in Regeneron's late-stage drug development.
Continuity snapshot
- Trend status: insufficient_history.
- Continuity stage: emerging_confirmed.
- Current status: open.
- 3 current source-linked posts are attached to this storyline.
All evidence
All evidence
Regeneron immunotherapy combo comes up short in melanoma trial
BioPharma Dive · biopharmadive.com · 2026-05-18 11:55 UTC
Another LAG-3 setback as Regeneron drug fails phase 3 trial
pharmaphorum · pharmaphorum.com · 2026-05-18 09:19 UTC
A phase 3 trial of Regeneron’s LAG-3 inhibitor has missed its primary endpoint, leaving the biopharma reeling from the second failure of a key late-stage program in the past year.
Fierce Biotech · fiercebiotech.com · 2026-05-18 08:58 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 3Origin domains: 3Duplicates: -
Showing 3 / 0
Top publishers (this list)
- BioPharma Dive (1)
- pharmaphorum (1)
- Fierce Biotech (1)
Top origin domains (this list)
- biopharmadive.com (1)
- pharmaphorum.com (1)
- fiercebiotech.com (1)